The authors proposed that defactinib is an attractive molecule for repurposing to treat patients with UC or other inflammatory conditions, such as arthritis, acute lung injury, or atherosclerosis, in which IRF5 function in macrophages has been intimately linked to pathogenicity [34]. The gene discussed is IRF5; the disease is Arthritis.